These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35561305)

  • 1. The impact of COVID-19 on routine vaccinations in Taiwan and an unexpected surge of pneumococcal vaccination.
    Chiu NC; Lo KH; Chen CC; Huang SY; Weng SL; Wang CJ; Kuo HH; Chi H; Lien CH; Tai YL; Lin CY
    Hum Vaccin Immunother; 2022 Nov; 18(5):2071079. PubMed ID: 35561305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The COVID-19 pandemic increased the demand for pneumococcal vaccination in Japan.
    Komori A; Mori H; Naito T
    Hum Vaccin Immunother; 2021 Nov; 17(11):4673-4674. PubMed ID: 34357842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Coronavirus Infectious Disease (COVID-19) pandemic on willingness of immunization-A community-based questionnaire study.
    Chen PY; Chuang PN; Chiang CH; Chang HH; Lu CW; Huang KC
    PLoS One; 2022; 17(1):e0262660. PubMed ID: 35030220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementing a Nurse-Driven Protocol for Pneumococcal Vaccination in an Academic Rheumatology Clinic.
    Joerns EK; Pokala N; Bermas B; Reisch J; Wang DC; Arasaratnam R; Bajaj P
    J Rheumatol; 2023 Mar; 50(3):413-419. PubMed ID: 36319017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of COVID-19 and catch-up strategies on routine childhood vaccine coverage trends in Latin America: A systematic literature review and database analysis.
    Castrejon MM; Leal I; de Jesus Pereira Pinto T; Guzmán-Holst A
    Hum Vaccin Immunother; 2022 Nov; 18(6):2102353. PubMed ID: 36084255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel.
    Ben-Shimol S; Givon-Lavi N; Greenberg D; Dagan R
    Hum Vaccin Immunother; 2016; 12(2):268-76. PubMed ID: 26430921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric parapneumonic effusion before and after national pneumococcal vaccination programs in Taiwan.
    Sim JY; Chang LY; Chang TH; Chen JM; Lee PI; Huang LM; Lu CY
    J Formos Med Assoc; 2020 Nov; 119(11):1608-1618. PubMed ID: 32747171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the different 13-valent pneumococcal conjugate vaccination uptakes on the invasive pneumococcal disease in children: Analysis of a hospital-based and population-based surveillance study in Madrid, Spain, 2007-2015.
    Picazo J; Ruiz-Contreras J; Casado-Flores J; Negreira S; Baquero F; Hernández-Sampelayo T; Otheo E; Méndez C;
    PLoS One; 2017; 12(2):e0172222. PubMed ID: 28207888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study.
    Desmet S; Lagrou K; Wyndham-Thomas C; Braeye T; Verhaegen J; Maes P; Fieuws S; Peetermans WE; Blumental S
    Lancet Infect Dis; 2021 Jan; 21(1):127-136. PubMed ID: 32702303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
    Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
    Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the COVID-19 pandemic on routine immunization services in Yerevan and vaccinations against COVID-19 in Armenia.
    Melkonyan N; Badalyan A; Hovhannisyan H; Poghosyan K
    J Infect Dev Ctries; 2022 Nov; 16(11):1687-1695. PubMed ID: 36449639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.
    Earnshaw SR; McDade CL; Zanotti G; Farkouh RA; Strutton D
    BMC Infect Dis; 2012 Apr; 12():101. PubMed ID: 22530841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of 13-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Carriage Rates of Streptococcus pneumoniae in a Rural Community in the Dominican Republic.
    Dunn MG; Lessa FC; Sánchez J; Cordero R; Feris-Iglesias J; Cedano D; Carvalho MDG; Fernández J; Feemster KA
    J Infect Dis; 2021 Sep; 224(12 Suppl 2):S237-S247. PubMed ID: 34469551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of pneumococcal conjugate vaccine in children on the serotypic epidemiology of adult invasive pneumococcal diseases in Taiwan.
    Chi HC; Hsieh YC; Tsai MH; Lee CH; Kuo KC; Huang CT; Huang YC
    J Microbiol Immunol Infect; 2018 Jun; 51(3):332-336. PubMed ID: 28082066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.
    Wu DB; Roberts C; Lee VW; Hong LW; Tan KK; Mak V; Lee KK
    Hum Vaccin Immunother; 2016; 12(2):403-16. PubMed ID: 26451658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
    Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States.
    McGarry LJ; Gilmore KE; Rubin JL; Klugman KP; Strutton DR; Weinstein MC
    BMC Infect Dis; 2013 May; 13():229. PubMed ID: 23687999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study.
    Ricketson LJ; Bettinger JA; Sadarangani M; Halperin SA; Kellner JD;
    Vaccine; 2022 Apr; 40(19):2733-2740. PubMed ID: 35351324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards the introduction of pneumococcal conjugate vaccines in Bhutan: A cost-utility analysis to determine the optimal policy option.
    Dorji K; Phuntsho S; Pempa ; Kumluang S; Khuntha S; Kulpeng W; Rajbhandari S; Teerawattananon Y
    Vaccine; 2018 Mar; 36(13):1757-1765. PubMed ID: 29478752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
    Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
    PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.